Juan Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Juan Zhang has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Mengqi Yang
College of the First Clinical Medical, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China
2 shared publications - Yi-Tao Xue
Affiliated Hospital of Shandong University of traditional Chinese Medicine
2 shared publications - Cundong Fan
Department of Neurology, The Second Affiliated Hospital of Shandong First Medical University, Taian, Shandong Province, 271000, China
1 shared publication Huachen Jiao
Cardiology Department, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, 250014, People’s Republic of China
1 shared publication- Huachen Jiao
Department of Cardiology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China
1 shared publication Jie Cui
Department of Neurology
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by Wiley in Journal of Diabetes Research
- Vol. 2025 (1) , 7578626
Mechanistic Insights Into Qidan Yixin Decoction for Diabetic Cardiomyopathy via Macrophage Polarization
Background: Diabetic cardiomyopathy (DCM) has a multifactorial etiology, and no specific treatment is available for its management. Qidan Yixin decoction (QDYXD) demonstrated encouraging clinical results in treating DCM; however, its underlying mechanics are yet unclear. Methods: Network pharmacology was applied to determine the active ingredients and targets of QDYXD. The GeneCards and GEO databases were used to retrieve genes associated with DCM and macrophage polarization. These targets were subjected to GO and KEGG enrichment analyses, immune infiltration study, and PPI network design. The core targets were further refined using SVM‐RFE, LASSO, and random forest algorithms. Docking the core targets with the main active components followed. For experimental validation, rat models were created. Results: There were 48 potential targets in all. Quercetin, methyl palmitate, luteolin, and tanshinone IIA were identified as the primary active components. Enrichment analysis indicated that one of the key pathways associated with the potential targets was the signaling pathway of HIF‐1. Machine learning techniques were used to identify two core targets, LDHA and PGK1. Animal experiments demonstrated that QDYXD can suppress the upregulation of PGK1, LDHA, and HIF1A; block the polarization of M1 macrophages; and considerably enhance DCM rats’ cardiac function. Conclusion: QDYXD improves cardiac function in DCM by attenuating M1 macrophage polarization and inhibiting the HIF‐1 signaling pathway, specifically through the modulation of PGK1, LDHA, and HIF1A. This study provides preliminary insights into how QDYXD modulates macrophage polarization during DCM treatment. Moreover, the identification of potential active components and core molecular targets of QDYXD offers promising directions for future drug development in DCM therapy.
- 1 January 2025
- Published by Wiley in Journal of Diabetes Research
- Vol. 2025 (1) , 7578626
Open AccessMechanistic Insights Into Qidan Yixin Decoction for Diabetic Cardiomyopathy via Macrophage Polarization
Background: Diabetic cardiomyopathy (DCM) has a multifactorial etiology, and no specific treatment is available for its management. Qidan Yixin decoction (QDYXD) demonstrated encouraging clinical results in treating DCM; however, its underlying mechanics are yet unclear. Methods: Network pharmacology was applied to determine the active ingredients and targets of QDYXD. The GeneCards and GEO databases were used to retrieve genes associated with DCM and macrophage polarization. These targets were subjected to GO and KEGG enrichment analyses, immune infiltration study, and PPI network design. The core targets were further refined using SVM‐RFE, LASSO, and random forest algorithms. Docking the core targets with the main active components followed. For experimental validation, rat models were created. Results: There were 48 potential targets in all. Quercetin, methyl palmitate, luteolin, and tanshinone IIA were identified as the primary active components. Enrichment analysis indicated that one of the key pathways associated with the potential targets was the signaling pathway of HIF‐1. Machine learning techniques were used to identify two core targets, LDHA and PGK1. Animal experiments demonstrated that QDYXD can suppress the upregulation of PGK1, LDHA, and HIF1A; block the polarization of M1 macrophages; and considerably enhance DCM rats’ cardiac function. Conclusion: QDYXD improves cardiac function in DCM by attenuating M1 macrophage polarization and inhibiting the HIF‐1 signaling pathway, specifically through the modulation of PGK1, LDHA, and HIF1A. This study provides preliminary insights into how QDYXD modulates macrophage polarization during DCM treatment. Moreover, the identification of potential active components and core molecular targets of QDYXD offers promising directions for future drug development in DCM therapy.
- Top Cited Papers
- 10 June 2023
- Published by Elsevier in Microvascular Research
- Vol. 149, 104565
Myocardial ischemia-reperfusion injury; Molecular mechanisms and prevention
- 10 June 2023
- Published by Elsevier in Microvascular Research
- Vol. 149, 104565
Top Cited PapersMyocardial ischemia-reperfusion injury; Molecular mechanisms and prevention
- 29 April 2023
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 396 (10) , 2269-2286
Broadening horizons: The role of ferroptosis in myocardial ischemia–reperfusion injury
Ferroptosis is a novel type of regulated cell death (RCD) discovered in recent years, where abnormal intracellular iron accumulation leads to the onset of lipid peroxidation, which further leads to the disruption of intracellular redox homeostasis and triggers cell death. Iron accumulation with lipid peroxidation is considered a hallmark of ferroptosis that distinguishes it from other RCDs. Myocardial ischemia–reperfusion injury (MIRI) is a process of increased myocardial cell injury that occurs during coronary reperfusion after myocardial ischemia and is associated with high post-infarction mortality. Multiple experiments have shown that ferroptosis plays an important role in MIRI pathophysiology. This review systematically summarized the latest research progress on the mechanisms of ferroptosis. Then we report the possible link between the occurrence of MIRI and ferroptosis in cardiomyocytes. Finally, we discuss and analyze the related drugs that target ferroptosis to attenuate MIRI and its action targets, and point out the shortcomings of the current state of relevant research and possible future research directions. It is hoped to provide a new avenue for improving the prognosis of the acute coronary syndrome.
- 29 April 2023
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 396 (10) , 2269-2286
Broadening horizons: The role of ferroptosis in myocardial ischemia–reperfusion injury
Ferroptosis is a novel type of regulated cell death (RCD) discovered in recent years, where abnormal intracellular iron accumulation leads to the onset of lipid peroxidation, which further leads to the disruption of intracellular redox homeostasis and triggers cell death. Iron accumulation with lipid peroxidation is considered a hallmark of ferroptosis that distinguishes it from other RCDs. Myocardial ischemia–reperfusion injury (MIRI) is a process of increased myocardial cell injury that occurs during coronary reperfusion after myocardial ischemia and is associated with high post-infarction mortality. Multiple experiments have shown that ferroptosis plays an important role in MIRI pathophysiology. This review systematically summarized the latest research progress on the mechanisms of ferroptosis. Then we report the possible link between the occurrence of MIRI and ferroptosis in cardiomyocytes. Finally, we discuss and analyze the related drugs that target ferroptosis to attenuate MIRI and its action targets, and point out the shortcomings of the current state of relevant research and possible future research directions. It is hoped to provide a new avenue for improving the prognosis of the acute coronary syndrome.
- Open Access
- 16 September 2022
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 16, 3145-3168
Guanmaitong Granule Attenuates Atherosclerosis by Inhibiting Inflammatory Immune Response in ApoE−/− Mice Fed High-Fat Diet
Background: Atherosclerosis (AS) is the leading cause of cardiovascular diseases, such as myocardial infarction and stroke. Guanmaitong granule (GMTG) is a TCM (Traditional Chinese medicine) prescribed to treat AS. However, its mechanism remains unclear. Methods: We obtained reliable ingredients and targets of GMTG using the HERB database. AS-related targets were obtained from HERB and GeneCards databases. The target database was constructed by intersecting the ingredients of GMTG with the AS-related targets. STRING and Cytoscape were used to create protein-protein interaction (PPI) network and screen core targets. GO enrichment analysis and KEGG pathway analyses were performed using R. Finally, the ApoE−/− mice AS model was induced by a high-fat diet (HFD) for in vivo validation of core pathways and targets. Results: A total of 124 ingredients and 418 potential targets of GMTG for treating AS were obtained. Numerous ingredients and targets were related to Panax notoginseng, Salvia miltiorrhiza, and Astragalus. Most core targets and pathways were involved in the inflammatory immune response. GMTG could decrease serum triglycerides, total cholesterol, low-density lipoprotein-cholesterol, and oxidized low-density lipoprotein level and increase the serum high-density lipoprotein-cholesterol level. Furthermore, GMTG reduced the plaque burden and promoted plaque remodeling by reducing plaque area, lipid deposition, foam cell content, and collagen fiber content in the plaque in the aortic root of ApoE−/− mice. GMTG inhibited systemic and plaque inflammatory immune response and increased plaque stability by inhibiting the excessive release of the TLR4/MyD88/NF-κB pathway-induced inflammatory cytokines, tumor necrosis factor, interleukin-6, and interleukin-1 beta. Conclusion: Radix notoginseng, Radix salviae liguliobae, and Radix astragali are the main ingredients of GMTG for treating AS. Further, GMTG could regulate the level of serum lipids and inhibit inflammatory immune response, which resulted in anti-AS effects such as plaque stabilization, reduction of plaque burden, and plaque remodeling. GMTG is a promising multi-target treatment for AS.
- 16 September 2022
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 16, 3145-3168
Open AccessGuanmaitong Granule Attenuates Atherosclerosis by Inhibiting Inflammatory Immune Response in ApoE−/− Mice Fed High-Fat Diet
Background: Atherosclerosis (AS) is the leading cause of cardiovascular diseases, such as myocardial infarction and stroke. Guanmaitong granule (GMTG) is a TCM (Traditional Chinese medicine) prescribed to treat AS. However, its mechanism remains unclear. Methods: We obtained reliable ingredients and targets of GMTG using the HERB database. AS-related targets were obtained from HERB and GeneCards databases. The target database was constructed by intersecting the ingredients of GMTG with the AS-related targets. STRING and Cytoscape were used to create protein-protein interaction (PPI) network and screen core targets. GO enrichment analysis and KEGG pathway analyses were performed using R. Finally, the ApoE−/− mice AS model was induced by a high-fat diet (HFD) for in vivo validation of core pathways and targets. Results: A total of 124 ingredients and 418 potential targets of GMTG for treating AS were obtained. Numerous ingredients and targets were related to Panax notoginseng, Salvia miltiorrhiza, and Astragalus. Most core targets and pathways were involved in the inflammatory immune response. GMTG could decrease serum triglycerides, total cholesterol, low-density lipoprotein-cholesterol, and oxidized low-density lipoprotein level and increase the serum high-density lipoprotein-cholesterol level. Furthermore, GMTG reduced the plaque burden and promoted plaque remodeling by reducing plaque area, lipid deposition, foam cell content, and collagen fiber content in the plaque in the aortic root of ApoE−/− mice. GMTG inhibited systemic and plaque inflammatory immune response and increased plaque stability by inhibiting the excessive release of the TLR4/MyD88/NF-κB pathway-induced inflammatory cytokines, tumor necrosis factor, interleukin-6, and interleukin-1 beta. Conclusion: Radix notoginseng, Radix salviae liguliobae, and Radix astragali are the main ingredients of GMTG for treating AS. Further, GMTG could regulate the level of serum lipids and inhibit inflammatory immune response, which resulted in anti-AS effects such as plaque stabilization, reduction of plaque burden, and plaque remodeling. GMTG is a promising multi-target treatment for AS.
- Open Access
- 5 January 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 1733834
Calycosin Alleviates Doxorubicin‐Induced Cardiotoxicity and Pyroptosis by Inhibiting NLRP3 Inflammasome Activation
Calycosin (CAL) is the main active component present in Astragalus and reportedly possesses diverse pharmacological properties. However, the cardioprotective effect and underlying mechanism of CAL against doxorubicin‐ (DOX‐) induced cardiotoxicity need to be comprehensively examined. Herein, we aimed to investigate whether the cardioprotective effects of CAL are related to its antipyroptotic effect. A cardiatoxicity model was established by stimulating H9c2 cells and C57BL/6J mice using DOX. In vitro, CAL increased H9c2 cell viability and decreased DOX‐induced pyroptosis via NLRP3, caspase‐1, and gasdermin D signaling pathways in a dose‐dependent manner. In vivo, CAL‐DOX cotreatment effectively suppressed DOX‐induced cytotoxicity as well as inflammatory and cardiomyocyte pyroptosis via the same molecular mechanism. Next, we used nigericin (Nig) and NLRP3 forced overexpression to determine whether CAL imparts antipyroptotic effects by inhibiting the NLRP3 inflammasome in vitro. Furthermore, CAL suppressed DOX‐induced mitochondrial oxidative stress injury in H9c2 cells by decreasing the generation of reactive oxygen species and increasing mitochondrial membrane potential and adenosine triphosphate. Likewise, CAL attenuated the DOX‐induced increase in malondialdehyde content and decreased superoxide dismutase and glutathione peroxidase activities in H9c2 cells. In vivo, CAL afforded a protective effect against DOX‐induced cardiac injury by improving myocardial function, inhibiting brain natriuretic peptide, and improving the changes of the histological morphology of DOX‐treated mice. Collectively, our findings confirmed that CAL alleviates DOX‐induced cardiotoxicity and pyroptosis by inhibiting NLRP3 inflammasome activation in vivo and in vitro.
- 5 January 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 1733834
Open AccessCalycosin Alleviates Doxorubicin‐Induced Cardiotoxicity and Pyroptosis by Inhibiting NLRP3 Inflammasome Activation
Calycosin (CAL) is the main active component present in Astragalus and reportedly possesses diverse pharmacological properties. However, the cardioprotective effect and underlying mechanism of CAL against doxorubicin‐ (DOX‐) induced cardiotoxicity need to be comprehensively examined. Herein, we aimed to investigate whether the cardioprotective effects of CAL are related to its antipyroptotic effect. A cardiatoxicity model was established by stimulating H9c2 cells and C57BL/6J mice using DOX. In vitro, CAL increased H9c2 cell viability and decreased DOX‐induced pyroptosis via NLRP3, caspase‐1, and gasdermin D signaling pathways in a dose‐dependent manner. In vivo, CAL‐DOX cotreatment effectively suppressed DOX‐induced cytotoxicity as well as inflammatory and cardiomyocyte pyroptosis via the same molecular mechanism. Next, we used nigericin (Nig) and NLRP3 forced overexpression to determine whether CAL imparts antipyroptotic effects by inhibiting the NLRP3 inflammasome in vitro. Furthermore, CAL suppressed DOX‐induced mitochondrial oxidative stress injury in H9c2 cells by decreasing the generation of reactive oxygen species and increasing mitochondrial membrane potential and adenosine triphosphate. Likewise, CAL attenuated the DOX‐induced increase in malondialdehyde content and decreased superoxide dismutase and glutathione peroxidase activities in H9c2 cells. In vivo, CAL afforded a protective effect against DOX‐induced cardiac injury by improving myocardial function, inhibiting brain natriuretic peptide, and improving the changes of the histological morphology of DOX‐treated mice. Collectively, our findings confirmed that CAL alleviates DOX‐induced cardiotoxicity and pyroptosis by inhibiting NLRP3 inflammasome activation in vivo and in vitro.